It just isn't logical that a diagnostic testing company (who was interested in partnering the serum RECAF technology) would disclose to BioCurex any of the due diligence information they gather before signing a deal. That would include any laboratory studies they conduct to confirm the technology. If the data is fantastic, as in yesterday's press release, why would the perspective new partner disclose that information to BioCurex (and to the whole world including other competitors) and potentially run the price up on themselves before signing the deal?
Yesterday's press release appears to be a study conducted for or by BioCurex to establish something like proof-of-concept on the use of RECAF technology for the early detection of breast cancer. It also seems logical that Abbott already knows all they need to know to be very interested in negotiating an exclusivity agreement on serum RECAF. And therein lies the beauty of the deal Dr. Moro made originally with Abbott. That deal only had 200K up front money but it got the world's largest diagnostic company involved with RECAF. Exclusivity with Abbott should bring in the big bucks. My guess would be that an exclusive deal for using blood tests for the early detection of breast cancer in stages I and II would be worth millions and millions of up front dollars. Abbott, with an exclusive license, would then sell off sublicenses to other companies who want to use the test in their brand of automated analyzers. BioCurex has a lot of leverage here. If Abbott does not go for exclusivity, other diagnostic companies can pay Biocurex for a semi-exclusive license and bypass Abbott's royalities on a sublicense deal. kag
AI
